mizoribine 🐢 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
ribofuranyl-derivatives of the "pyrazofurin" type 3363 50924-49-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mizoribine
  • bredinin
  • beta-Bredinin
imidazole nucleoside with immunosuppressive activity isolated from culture filtrate of Eupenicillium brefeldianum; structure
  • Molecular weight: 259.22
  • Formula: C9H13N3O6
  • CLOGP: -1.36
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 5
  • TPSA: 151.06
  • ALOGS: -0.86
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 51 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 0.91 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 42.72 31.46 16 1075 24514 63463417
Pharyngitis 38.23 31.46 14 1077 20129 63467802
Hyperuricaemia 36.99 31.46 10 1081 5360 63482571
Hyperlipidaemia 34.92 31.46 13 1078 19558 63468373
Iron deficiency anaemia 34.67 31.46 13 1078 19956 63467975
Angiocentric lymphoma 31.92 31.46 6 1085 625 63487306

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 40.45 29.87 20 1906 42624 79699838
Pharyngitis 38.81 29.87 16 1910 22359 79720103
N-telopeptide urine increased 36.96 29.87 5 1921 42 79742420
Osteonecrosis 36.85 29.87 17 1909 31078 79711384
Kidney transplant rejection 34.86 29.87 12 1914 10234 79732228
Iron deficiency anaemia 33.46 29.87 15 1911 25657 79716805
Hyperlipidaemia 33.23 29.87 15 1911 26078 79716384
Hyperuricaemia 33.20 29.87 12 1914 11787 79730675

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000962 Antimalarials
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐢 Veterinary Drug Use

None

🐢 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.79 acidic
pKa2 11.55 acidic
pKa3 11.83 acidic
pKa4 12.51 acidic
pKa5 13.19 acidic
pKa6 3.13 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01392 KEGG_DRUG
C0128608 UMLSCUI
CHEBI:31858 CHEBI
MZR PDB_CHEM_ID
CHEMBL245019 ChEMBL_ID
DB12617 DRUGBANK_ID
C010052 MESH_SUPPLEMENTAL_RECORD_UI
104762 PUBCHEM_CID
5120 INN_ID
4JR41A10VP UNII
772627008 SNOMEDCT_US

Pharmaceutical products:

None